Lantibiotics, lantibiotic-producing bacteria, compositions and methods of production and use thereof
AssigneeMemorial Sloan Kettering Cancer Center
InventorsEric Pamer, Sohn Kim, Peter McKenney, Silvia Caballero
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to novel lantibiotics, lantibiotic pharmaceutical compositions, isolated and recombinant lantibiotic-producing bacteria, bacterial pharmaceutical compositions, methods of producing novel lantibiotics from lantibiotic-producing bacteria, and methods of using such lantibiotics, lantibiotic pharmaceutical compositions, and bacterial pharmaceutical compositions to treat gram-positive bacteria infections, including vancomycin resistant enterococci infections, in patients, and to treat food and other objects to avoid gram-positive bacteria contamination.
Claims19
A pharmaceutical composition comprising a lantibiotic comprising a domain having the amino acid sequence of SEQ. ID. No.:
- 3 and a pharmaceutically acceptable carrier.
A method of treating a gram-positive bacteria colonization or infection, the method comprising administering to a patient in need of such treatment, a therapeutically effective amount of a composition comprising (i) a lantibiotic comprising a domain having the amino acid sequence of SEQ. ID. No.:
- 3 and/or (ii) an isolated lantibiotic-producing B. producta bacteria comprising at least one nucleic acid comprising a nucleic acid having the sequence of SEQ. ID. No.:
- 5, 6, 7, 8, 9, 10, 11, 12, 13, and/or 14 and operable to produce a lantibiotic having the sequence of SEQ. ID. No.:
- 3.
A bacterial pharmaceutical composition comprising
- (a) a lantibiotic-producing B. producta bacteria comprising a nucleic acid comprising the sequence of SEQ. ID. No.:
- 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 and operable to produce a lantibiotic having the sequence of SEQ. ID. No.:
- 3;
- and
- (b) a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.